Core Viewpoint - Intercont (Cayman) Limited will implement a 25-for-1 reverse share split effective April 2, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][3]. Group 1: Share Consolidation Details - The reverse share split will result in every 25 shares being combined into one share, reducing the total number of authorized ordinary shares from 1,000,000,000 to 40,000,000 [4]. - The par value of the shares will change to $0.0025 per share, and no fractional shares will be issued; any resulting fractional shares will be rounded up [4]. - The company's Class A ordinary shares will continue to trade under the symbol "NCT" but will have a new CUSIP number, G48049111, post-split [2]. Group 2: Shareholder Approval and Implementation - Shareholders approved the reverse split and granted the board the authority to determine the final ratio and timing if the share price fell below $1.00 within 180 days of the approval at an Extraordinary General Meeting on January 26, 2026 [3]. - The board of directors approved the 25-for-1 ratio on March 22, 2026, for implementation [3]. Group 3: Shareholder Actions - Registered stockholders holding shares in book-entry form will not need to take any action to receive their post-split shares [5]. - Stockholders with shares in brokerage accounts will have their positions automatically adjusted according to their brokers' processes [5]. Group 4: Company Overview - Intercont (Cayman) Limited is a global shipping enterprise focused on environmentally friendly transportation solutions and innovative business models [6].

Core Viewpoint - XORTX Therapeutics Inc. has delayed its share consolidation from March 27, 2026, to April 6, 2026, pending necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange [1] Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease [2] - The company has three clinically advanced products: 1. XRx-026 for gout treatment 2. XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) 3. XRx-101 for acute kidney injury related to respiratory virus infections - Additionally, XORTX is developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [2] - The company aims to target aberrant purine metabolism and xanthine oxidase to reduce uric acid production [2]

Core Viewpoint - Autozi Internet Technology (Global) Ltd. has announced a share consolidation on a 10 for 1 ratio to regain compliance with Nasdaq listing requirements, effective March 23, 2026 [1][2]. Group 1: Share Consolidation Details - The share consolidation will convert every 10 ordinary shares into one issued and outstanding ordinary share, with no fractional shares issued [3]. - The authorized share capital will change from US$500,000 divided into 9,600,000,000 Class A ordinary shares of US$0.00005 par value each to US$500,000 divided into 960,000,000 Class A ordinary shares of US$0.0005 par value each [4]. - The total issued and outstanding Class A ordinary shares will decrease from 44,891,221 to approximately 4,489,123, while Class B ordinary shares will decrease from 613,102 to approximately 61,311 [4]. Group 2: Company Overview - Autozi is a leading provider of lifecycle automotive services in China, founded in 2010, offering a range of automotive products and services through online and offline channels [5]. - The company utilizes an advanced online supply chain cloud platform and SaaS solutions to create a dynamic ecosystem that enhances collaboration and efficiency in the automotive industry [5].

Core Viewpoint - Fitness Champs Holdings Limited has announced a share consolidation on a 15 for 1 ratio to regain compliance with Nasdaq listing requirements, effective March 23, 2026 [1][2]. Group 1: Share Consolidation Details - The share consolidation will automatically convert every 15 ordinary shares into one issued and outstanding ordinary share without requiring action from shareholders [3]. - No fractional shares will be issued; shareholders will receive one full share in lieu of any fractional share resulting from the consolidation [3]. - The authorized share capital will be reclassified from US$500,000 divided into 100,000,000,000 shares to US$500,000 divided into 80,000,000,000 Class A ordinary shares, 10,000,000,000 Class B ordinary shares, and 10,000,000,000 preferred shares [4]. Group 2: Company Overview - Fitness Champs Holdings Limited is a prominent aquatic sports education provider in Singapore, offering swimming lessons and aquatic sports classes [5]. - The company is a major provider of swimming lessons to children in public schools through the SwimSafer program and has been operating since 2012 [5]. - Future plans include expanding into other sports such as pickleball, aiming to diversify its offerings [5].

Core Viewpoint - Optimi Health Corp. has initiated an underwritten public offering of its common shares in the United States as part of its strategy to list on the Nasdaq Capital Market [1][2] Group 1: Offering Details - The offering will be managed by Joseph Gunnar & Co., LLC, and the company has applied to list its shares on Nasdaq under the symbol "OPTH" [2] - The offering is subject to market conditions and the completion of the SEC and Nasdaq review process, with no assurance on the timing or terms of completion [4][16] - The offering will be conducted under a prospectus as part of an effective registration statement filed with the SEC [3] Group 2: Share Consolidation - The company's board has approved a consolidation of its outstanding shares at a ratio of one post-consolidation share for every thirty pre-consolidation shares [7] - This consolidation aims to meet Nasdaq's minimum share price requirement and will not affect shareholders' proportionate ownership, except for fractional shares [8][9] - Following the consolidation, the company expects to have approximately 3,225,897 shares outstanding [9] Group 3: Company Overview - Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies [12] - The company produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada [12] - Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally [13]

Core Viewpoint - XORTX Therapeutics Inc. has received recommendations from independent proxy advisory firms, including ISS, to vote "FOR" the share consolidation at the upcoming shareholder meeting on March 24, 2026, which could enhance the company's long-term growth prospects [1][2]. Share Consolidation - ISS stated that the stock consolidation should have no direct impact on shareholder value and could broaden financing alternatives for the company [2]. - The Board of Directors of XORTX recommends that shareholders vote FOR all proposed resolutions [3][6]. Voting Information - The proxy voting deadline is set for March 20, 2026, and shareholders are encouraged to vote in advance to ensure timely submission [4][6]. - Shareholders of record as of February 20, 2026, are eligible to vote at the meeting [4]. Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [5][7]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [5].

Core Viewpoint - Aeries Technology, Inc. has received shareholder approval for share consolidation resolutions but does not plan to implement them in the near term [2] Group 1: Share Consolidation - Shareholders approved share consolidation resolutions at a ratio of up to one-for-ten (1:10), with the exact ratio to be determined by the Board [2] - The Board retains the authority to implement the share consolidation before the next annual general meeting, if deemed appropriate [2] Group 2: Share Repurchase Program - The Company is focused on enhancing operational performance and has authorized a $5.0 million share repurchase program to buy back Class A ordinary shares [3] - Repurchases will occur at management's discretion regarding amounts and prices [3] Group 3: Company Overview - Aeries Technology, Inc. is a leader in AI-powered business transformation and Global Capability Center (GCC) services [4] - The Company collaborates with private equity firms and enterprise clients to establish global capability centers aimed at driving operational efficiency and long-term value creation [4]

Core Viewpoint - Garden Stage Limited is consolidating its Class A shares on a 200 for 1 ratio to regain compliance with Nasdaq listing requirements, effective March 6, 2026 [2][3]. Group 1: Share Consolidation Details - The consolidation will convert every 200 Class A Shares into one Class A Share with a par value of US$0.02, without requiring action from shareholders [3]. - Fractional shares resulting from the consolidation will be cancelled and returned to the pool of authorized but unissued shares [3]. - Prior to the consolidation, there are 282,485,623 Class A Shares and 9,250,000 Class B Shares outstanding [4]. Group 2: Post-Consolidation Share Structure - After the consolidation, the total number of issued and outstanding Class A Shares will be approximately 1,412,428, while the number of Class B Shares will remain at 9,250,000 [4]. Group 3: Company Overview - Garden Stage Limited is a financial services provider based in Hong Kong, primarily engaged in placing and underwriting services, securities dealing and brokerage services, and asset management services [1]. - The company operates through two wholly-owned subsidiaries: I Win Securities Limited and I Win Asset Management Limited, both licensed under the Securities and Futures Ordinance in Hong Kong [5].

Core Viewpoint - PTL Limited has announced the approval of a 1-for-80 share consolidation of its Class A and Class B ordinary shares to regain compliance with Nasdaq listing requirements [1][2]. Share Consolidation Details - The share consolidation will take effect on February 27, 2026, with Class A Ordinary Shares trading under the same symbol "PTLE" but with a new CUSIP number G7377S127 [2]. - Currently, there are 491,237,500 Class A Ordinary Shares and 11,250,000 Class B Ordinary Shares outstanding. Post-consolidation, there will be 6,140,469 Class A Ordinary Shares and 140,625 Class B Ordinary Shares outstanding [3]. - The consolidation will not result in fractional shares; any fractions will be rounded up to the next whole number [3]. Company Overview - PTL Limited is headquartered in Hong Kong and operates as a bunkering facilitator, providing marine fuel logistics services primarily for container ships, bulk carriers, general cargo vessels, and chemical tankers [4]. - The company targets the Asia Pacific market and leverages its established network within the marine fuel logistics industry to offer a one-stop solution for vessel refueling [4].

Core Viewpoint - Big Tree Cloud Holdings Limited has announced the implementation of a dual-class share structure and a 1-for-20 share consolidation, aimed at strengthening its market position and supporting future growth [1] Group 1: Share Consolidation - The company held an extraordinary general meeting on January 30, 2026, where shareholders approved the consolidation of every 20 ordinary shares into one ordinary share [1] - The reverse stock split will not alter any shareholder's percentage interest in the company's outstanding ordinary shares, except for adjustments from rounding up fractional shares [1] - The consolidated shares will begin trading on the Nasdaq Capital Market under the symbol "DSY" on February 12, 2026 [1] Group 2: Dual-Class Share Structure - The authorized share capital has been changed to US$50,000, divided into 25,000,000 shares, comprising 20,000,000 Class A ordinary shares and 5,000,000 Class B ordinary shares [1] - The company has redesignated existing shares, with 3,500,000 shares registered in the name of Ploutos Group Limited becoming Class B shares, while the remaining shares are designated as Class A shares [1] - All outstanding options, warrants, and other securities will be adjusted according to their respective terms following the share consolidation [1] Group 3: Management Commentary - A company spokesperson stated that the share consolidation and dual-class structure are significant milestones designed to support the next phase of growth and provide stability for executing long-term strategies [1] - The measures are intended to strengthen the corporate foundation and enhance governance, focusing on driving innovation and sustainable value for stakeholders [1] Group 4: Company Overview - Big Tree Cloud, founded in 2020, is positioned as an international capital platform focused on industrial integration and strategic investment in China's personal care industry [1] - The company is accelerating its expansion into the AI sector to capture growing market demand for AI skills, injecting fresh momentum into its development [1]